Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBI343 combination therapy in advanced malignant solid tumors
CTR20261057Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in Nonhematologic neoplasms, sponsored by InnoCare Pharma. Started Apr 2026; status: active.
02
Drugs
arcotatug tavatecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261057.